Adherence after treatment switch from a multiple tablet antiretroviral regimen to a single tablet antiretroviral regimen

Therapies ◽  
2021 ◽  
Author(s):  
Scott S. Sutton ◽  
Joseph Magagnoli ◽  
Tammy H. Cummings ◽  
James W. Hardin
Keyword(s):  
Treatment Switch

scholarly journals Effectiveness, Safety, and Costs of a Treatment Switch to Dolutegravir Plus Rilpivirine Dual Therapy in Treatment-Experienced HIV Patients

2017 ◽  
Vol 52 (1) ◽  
pp. 11-18 ◽  
Author(s):  
José Luis Revuelta-Herrero ◽  
Esther Chamorro-de-Vega ◽  
Carmen Guadalupe Rodríguez-González ◽  
Roberto Alonso ◽  
Ana Herranz-Alonso ◽  
...  
Keyword(s):  
Drug Interaction ◽  
Viral Load ◽  
Dual Therapy ◽  
Art Adherence ◽  
Integrase Inhibitors ◽  
Resistance Mutations ◽  
Safe Strategy ◽  
Treatment Switch ◽  
Effectiveness Endpoint ◽  
All Treatment

Background: Evidence about the use of dolutegravir (DTG) and rilpivirine (RPV) as an antiretroviral therapy (ART) in treatment-experienced patients is scarce. Objective: To explore the effectiveness, safety, and costs of switching to a DTG plus RPV regimen in this population. Methods: This observational, prospective study included all treatment-experienced patients who switched to DTG plus RPV between November 2014 and July 2016. Patients were excluded if resistance mutations to integrase inhibitors or RPV were found. The effectiveness endpoint was the proportion of patients who achieved virological suppression (viral load [VL] <50 copies/mL) at week 48 (W48). Safety (incidence of adverse events leading to discontinuation and laboratory abnormalities), adherence, and costs were analyzed. Results: A total of 35 patients were included, and 91.4% were virologically suppressed at baseline. Patients were treated with ART for a median of 14 years (interquartile range = 7-20). At W48, 91.4% of patients were virologically suppressed (95% CI = 77.0-98.2). Two of the 3 patients not suppressed at baseline achieved undetectable VL at W48, and 2 patients discontinued DTG plus RPV (intolerance and a drug-drug interaction). None of the virologically suppressed patients at baseline showed virological rebound through W48. There were no significant changes in lipid, liver, and renal profiles. The proportion of patients with an ART adherence >90% increased from 65.6% to 93.8% ( P = 0.004). The annual per-patient ART costs dropped by €665 ( P = 0.265). Conclusions: Switching to DTG plus RPV seems to be an effective and safe strategy. Significant improvements in patients’ adherence and costs were achieved.

scholarly journals Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis

2020 ◽  
Vol 37 (5) ◽  
pp. 2098-2115 ◽  
Author(s):  
Jashin J. Wu ◽  
Corey Pelletier ◽  
Brian Ung ◽  
Marc Tian ◽  
Ibrahim Khilfeh ◽  
...  
Keyword(s):  
Psoriatic Arthritis ◽  
Healthcare Costs ◽  
Treatment Switch

Clinical management of patients with hip and knee osteoarthritis: patient satisfaction with treatment switch

2013 ◽  
Vol 34 (6) ◽  
pp. 823-832 ◽  
Author(s):  
Sergio Gimenez ◽  
Beatriz Armada ◽  
Jesús Iturralde Iriso ◽  
Leovigildo Ginel Mendoza ◽  
Bárbara Fernández-Morales
Keyword(s):  
Patient Satisfaction ◽  
Knee Osteoarthritis ◽  
Clinical Management ◽  
Osteoarthritis Patient ◽  
Satisfaction With Treatment ◽  
Treatment Switch

A retrospective mirror-image review of outcomes following a treatment switch to risperidone long-acting injection

2011 ◽  
Vol 26 ◽  
pp. e136-e137
Author(s):  
Amanda Wheeler ◽  
Jane Vanderpyl ◽  
Mirjana Stojkovic ◽  
Nasir Ali Mirza
Keyword(s):  
Mirror Image ◽  
Treatment Switch ◽  
Long Acting

Association of changes in circulating cell-free plasma DNA (cfDNA) and circulating tumor cells (CTC) during treatment with clinical outcome from olaparib in castration-resistant prostate cancer (CRPC): Exploratory analyses from the TOPARP-A trial.

2017 ◽  
Vol 35 (6_suppl) ◽  
pp. 141-141 ◽  
Author(s):  
Joaquin Mateo ◽  
Helen Mossop ◽  
Jane Goodall ◽  
David Lorente ◽  
Nuria Porta ◽  
...  
Keyword(s):  
Progression Free Survival ◽  
P Value ◽  
Time Varying ◽  
Castration Resistant Prostate Cancer ◽  
Plasma Dna ◽  
Cox Models ◽  
Castration Resistant ◽  
Treatment Switch ◽  
Response Biomarkers ◽  
Time Varying Covariates

141 Background: Response biomarkers are needed to optimize treatment switch decisions in CRPC patients. CTC and cfDNA may have clinical utility as response biomarkers; we studied them during olaparib treatment in a phase II trial in CRCP (Mateo et al NEJM 2015). Methods: CTC were enumerated using CellSearch (Jannsen Diagnostics) and cfDNA was extracted with the QIASymphony circulating DNA kit (Qiagen) from blood samples taken at baseline, 4- and 8-weeks (wk) of therapy. Radiological progression-free survival (rPFS) was defined as time from starting treatment to progression by RECIST 1.1, bone scan (PCWG2) or death. Overall survival (OS) was defined as time from starting treatment to death. CTC changes were categorized based on conversion from ≥ 5 to < 5 CTC/7.5ml blood and on ≥ 30% decline (Lorente et al Eur Urol 2016). cfDNA changes were evaluated as percentage change from baseline (continuous and binary). The prognostic value of CTC and cfDNA changes were assessed by Landmark analysis and Cox models with time-varying covariates; p-value < 0.01 were considered significant to account for multiple tests. Results: Overall, 13/47 (28%) and 16/42 (38%) evaluable patients had a CTC conversion at 4- and 8-wk respectively. A CTC conversion after 4-wk of olaparib associated with longer rPFS (median 8.9 vs 2.7 months [m], p = 0.001); a similar association was found at 8-wk. A 30% CTC decline at 4-wk also associated with longer rPFS (median 4.4 vs 2.6 m, p = 0.004). CTC conversion as a time-varying covariate associated with longer OS (HR 0.26, 95%CI 0.14-0.50, p < 0.001). Median baseline cfDNA was 31.6 ng/ml (IQR 19.4-57.1); 46 and 42 patients were evaluable for cfDNA changes at 4- and 8-wk. Percentage changes in cfDNA at 4- and 8- wk associated with rPFS (HR 1.01 and 1.005; p = 0.005 and 0.002 respectively) but association with OS was not significant. cfDNA declines ≥ 50% at 8- wk associated with longer rPFS (median 8.9 vs 2.7 m, p = 0.007) and OS (17.0 vs 10.1 m, p = 0.004). Conclusions: Decreases in CTC counts and cfDNA concentration associate with improved outcome from olaparib (rPFS, OS) in the TOPARP-A trial. Clinical trial information: NCT01682772.

Change in the clinical activity of multiple sclerosis after treatment switch for suboptimal response

2012 ◽  
Vol 19 (6) ◽  
pp. 899-904 ◽  
Author(s):  
J. Río ◽  
M. Tintoré ◽  
J. Sastre-Garriga ◽  
C. Nos ◽  
J. Castilló ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Clinical Activity ◽  
Treatment Switch

scholarly journals Influenza del trattamento della schizofrenia con neurolettici tipici o olanzapina sui costi sanitari e sugli outcomes lavorativi

2005 ◽  
Vol 6 (2) ◽  
pp. 93-96
Author(s):  
Angelomarco Barioglio ◽  
Luca Guidi ◽  
Giorgio Mariani
Keyword(s):  
Point Of View ◽  
Local Health ◽  
Neuroleptic Treatment ◽  
Medical Interventions ◽  
Olanzapine Treatment ◽  
Health Care Unit ◽  
Local Health Care ◽  
Schizophrenic Patients ◽  
Treatment Switch ◽  
Typical Neuroleptics

The aim of the present study was to evaluate the global treatment cost of schizophrenia with olanzapine or typical neuroleptics, according to Local Health Care Unit point of view. This analysis was performed through naturalistic observation of a cohort of schizophrenic patients referring to Ascoli Piceno ASL Department of Mental Health during 4 years (2001-2004). During year 2003, investigators have identified a cohort of patients who were undergoing treatment switch from typical neuroleptics to olanzapine. These patients, after the switch, are observed prospectively for the next 2 years and retrospectively for the last 2 years of treament. This method allow us to collect data about 4 years of treatment: 2 years of typical neuroleptic treatment followed by 2 years of olanzapine treatment. The present work is presenting the analysis of the first 3 years of observation. The results of our analysis are demonstrating that olanzapine treatment, through a better patient-physician alliance and with rehabilitative activities, allow lower total medical costs for the treatment of schizophrenia than typical neuroleptics. The higher acquisition cost of olanzapine versus typical neuroleptics was compensated by less hospitalizations and territorial medical interventions. During olanzapine treatment patients followed more rehabilitative activities (+71,26%, p

Sign in / Sign up

Export Citation Format

Share Document